Background/Aims: Keloids are fibrous overgrowths induced by cutaneous injury. MicroRNAs (miRNAs) have recently emerged as post-transcriptional gene repressors and participants in a diverse array of pathophysiological processes leading to skin disease. The purpose of the current study was to explore the precise functions of miR-181a in human keloid development and the underlying mechanisms. Methods: A miRNA microarray analysis was performed to compare expression profiles between keloid and normal skin tissues. Quantitative real-time PCR was conducted to estimate miR-181a expression. Cell proliferation was determined using the cell counting kit-8 (CCK-8) and 5-ethynyl-2-deoxyuridine (EdU) assays, and cell cycle and apoptosis were detected with flow cytometry. Direct targets of miR-181a were identified using the luciferase reporter assay. Results: miR-181a was significantly upregulated in human keloid tissues and fibroblasts, compared with their control counterparts. Overexpression of miR-181a enhanced keloid fibroblast DNA synthesis and proliferation and inhibited apoptosis, whereas miR-181a suppression triggered the opposite effects. Moreover, miR-181a suppressed the expression of PH domain leucine-rich repeat protein phosphatase 2 (PHLPP2) through direct interactions with its 3′UTR region and subsequently enhanced AKT activation. Overexpression of PHLPP2 without its 3′UTR attenuated the effects of miR-181a on cell proliferation and apoptosis in keloid fibroblast cells. Furthermore, miR-181a mimics increased normal skin fibroblast proliferation. Conclusions: Our results highlight a novel pathway mediated by miR181a, which may be effectively used as a therapeutic target for treatment of keloids.
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Introduction
Keloids are benign skin tumors characterized by histological accumulation of fibroblasts and excessive deposition of extracellular matrix (ECM) components that arise as a consequence of abnormal wound healing processes after skin injury [1, 2] . Although keloid is a benign dermal tumor, its management remains an excessively challenging clinical problem. Keloids do not regress with time, and surgical excision alone is associated with high rates of recurrence [1, 3] . Keloid disease is a recurrent fibroproliferative cutaneous tumor of unknown pathogenesis for which clinical management remains unsatisfactory. Elucidation of the etiopathogenesis and molecular mechanisms of keloid formation may facilitate the development of effective molecule-targeted therapies.
MicroRNAs (miRNAs) are noncoding, single-stranded small RNAs 21-25 nucleotides in length that mediate post-transcriptional repression to perform important cellular functions. MiRNAs partly suppress the expression of target genes through binding to their 3′ untranslated regions (UTR) and consequently influence a variety of physiological and pathological processes, including proliferation, metabolism, apoptosis, and invasion [4] [5] [6] . Emerging evidence has shown that miRNAs contribute to hypertrophic scarring or keloid formation [7] [8] [9] . Earlier, Zhang et al. [7] reported that miR-29a directly regulates the translation of various ECM mRNAs, such as the collagen superfamily, in fibrogenesis of keloids, suggesting utility as a novel marker for keloid. Downregulation of miR-125b in psoriatic skin has been shown to contribute to keratinocyte hyperproliferation [8] . Another miRNA microarray study focusing on differentially expressed miRNAs between keloid and normal skin tissue revealed that several miRNAs participate in the molecular network of keloid pathogenesis through regulating expression of their target genes [9] , of which only a fraction have been functionally characterized. In the current investigation, miRNA microarray analysis (employed to identify differentially expressed miRNAs between keloid and normal skin tissues) revealed a significant increase in miR-181a in keloid tissues. However, the functional roles of miR-181a and the relevant signaling pathways in the pathogenesis of human keloid fibroblasts remain to be validated.
Here, we confirmed upregulation of miR-181a in keloid tissue and keloid fibroblasts, compared with normal skin tissue and fibroblasts, respectively. Notably, miR-181a suppressed PHLPP2 expression, leading to activation of the AKT pathway, and consequently, acceleration of proliferation and suppression of apoptosis in human keloid fibroblasts. miR181a overexpression additionally enhanced the ability of normal fibroblasts to synthesize DNA. Our collective findings highlight potential biomarkers and targets that may be applied in diagnostic and therapeutic approaches for keloids.
Materials and Methods
Patient Samples Expression profiles of miRNAs in keloid tissue
Total RNAs were extracted from three paired samples of keloid and normal skin tissue using the miRcute miRNA Isolation Kit (Qiagen, Germany). In total, 500 ng RNA was subjected to the Agilent miRNA microarray analysis service (LC Sciences, Houston, TX, USA). Data analysis was performed with GenePix Pro software (LC Sciences) [11] . Statistical significance was examined using Student's t-test, and values of P<0.05 considered significant.
Western blot analysis
Western blotting was performed as described previously [12] . Total proteins were extracted from keloid tissues and fibroblasts using RIPA lysis buffer, separated using 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis, and transferred onto polyvinylidene difluoride membrane (Roche Life Sciences, Switzerland). Membranes were blocked with 5% skimmed milk and incubated with the appropriate antibodies. The anti-PHLPP2 antibody was obtained from Abcam, and phosphorylated Akt and AKT antibodies acquired from Cell Signaling Technology (Danvers, MA, USA). Primary antibodies were applied to the membrane, followed by horseradish-peroxidase-conjugated secondary antibodies. The antigen-antibody complex on the membrane was detected with enhanced chemiluminescence reagent (Thermo Scientific, Waltham, MA, USA).
Quantitative RT-PCR
Total RNA was obtained from cell lines using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Complementary DNA synthesis was performed using the PrimeScript reverse transcriptase reagent kit (Takara, Dalian, China) according to the manufacturer's protocol. qRT-PCR was conducted to detect the expression levels of miR-181a and PHLPP2 using SYBR ® Premix ExTaq (Takara). U6 or GAPDH served as the internal control for miRNA and mRNA.
Cell transfection
All synthetic miRNAs, including miR-181a mimic, miR-181a inhibitor and the respective controls, were purchased from Shanghai Genepharma (Shanghai, China). Human keloid fibroblasts were transfected with miR-181a mimic or miR-181a inhibitor using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions, and cells harvested after 24, 48, and 72 h to examine transfection efficiency. All procedures were performed in triplicate.
Reporter vector construction and luciferase reporter assay PHLPP2 wild-type (Wt) and mutant (Mut) 3′UTR were created and cloned into psiCHECK-2 luciferase reporter plasmid (Promega). For the luciferase assay, cells were plated intosix-well plates the day before transfection and cotransfected with the PHLPP2 Wt or Mut 3′UTR reporter vector and miR-181amimic or scramble control using Lipofectamine 2000 (Invitrogen). Luciferase activities were determined with the Dual-Luciferase Reporter System (Promega). All assays were performed in triplicate.
Cell proliferation assay
Human keloid fibroblast cell proliferation was measured using the CCK-8 (Beyotime Institute of Biotechnology, Jiangsu, China) and 5-ethynyl-2′-deoxyuridine (EdU) incorporation assay (Life Technologies Corporation, Carlsbad, CA, USA) kits, in keeping with the manufacturer's instructions. For the CCK-8 assay, cells were seeded into a 96-well plate andCCK-8 solution added. For the EdU incorporation assay, 5×10
Results
miR-181a is upregulated in human keloid tissues and fibroblasts
Differentially expressed miRNAs between three keloid and normal skin tissue sets were identified via miRNA microarray (Table 1 ). In particular, we focused on miR-181a, which displayed significantly increased expression in keloid tissues (Fig. 1A) . To further validate the miRNA microarray results, we evaluated miR-181a expression in 20 pairs of keloid and matched normal skin tissues, and additionally in keloid and normal fibroblasts, using qRT-PCR. As anticipated, miR-181a expression was markedly upregulated in both keloid tissues and fibroblasts, compared to the normal skin and fibroblast counterparts, respectively ( 
miR-181a enhances human keloid fibroblast DNA synthesis and proliferation
To explore the biological impact of miR-181a on human keloid fibroblasts, we performed gain-and loss-of-function experiments by transfecting keloid fibroblasts with a miR181a mimic and miR-181a inhibitor, respectively. The transfection efficiency of miR-181a was determined after 24, 48, and 72 h using qRT-PCR. miR-181a expression was remarkably enhanced in keloid fibroblasts transfected with the miR-181a mimic, compared with the scramble control, while expression was significantly decreased in cells transfected with the miR-181a inhibitor, relative to the negative control ( Fig. 2A) . Efficiency of transfection was not significantly different between the different time-points. The CCK-8 assay was employed to define the effects of miR-181a on cell proliferation. Our data revealed a significant increase in viability of miR-181a mimic-treated keloid fibroblasts than the scramble control group and suppression of viability of miR-181a inhibitor-treated cells, compared with the negative control group (Fig. 2B) . We additionally performed the EdU incorporation assay to confirm the function of miR-181a in cell proliferation. The number of EdU-positive keloid fibroblasts in the miR-181a mimic group was enhanced relative to that in cells from the scramble control group, and the EdU-positive keloid fibroblast number in the miR-181a inhibitor group was reduced, compared with the negative control group (Fig. 2C) . Consistently, expression of proliferation-related protein PCNA was increased in keloid fibroblasts transfected with the miR-181a mimic, and conversely, suppressed in cells transfected with the miR-181a inhibitor (Fig.  2D) . Furthermore, overexpression of miR-181a also promoted the cell cycle, and a decrease in the G0/ G1 fraction was observed in human keloid fibroblasts transfected with the miR181a mimic. Treatment with the miR-181a mimic led to a concomitant increase in the cell population in the S phase. Opposite results were obtained with the miR-181a inhibitor (Fig. 2E) . Enhanced expression levels of cell cycle-related proteins, including cyclin D1, cyclin E1 and CDK1 in keloid fibroblasts transfected with the miR-181a mimic and reduced in keloid fibroblasts transfected with the miR-181a inhibitor further confirmed that miR-181a promoted the cell cycle of keloid fibroblasts (Fig. 2F) . Our data clearly indicate that aberrant expression of miR-181a contributes to proliferation of keloid fibroblasts.
miR-181a inhibits human keloid fibroblast apoptosis
Next, we analyzed the effects of miR-181a on apoptosis using flow cytometry and western blot analyses. As shown in Fig. 3A and B, the miR-181a mimic induced a significant decrease in apoptotic death and expression of cleaved caspase-3 and caspase-9, indicating suppression of cell death in keloid fibroblasts transfected with the miR-181a mimic, compared with scramble control cells. Conversely, the miR-181a inhibitor enhanced apoptosis and expression of cleaved caspase-3 and caspase-9 in keloid fibroblasts. TUNEL staining data showed that miR-181a inhibits human keloid fibroblast apoptosis, consistent with flow cytometry findings (Fig. 3C) . Clearly, overexpression of miR-181a inhibits cell apoptosis, while its suppression promotes apoptosis in human keloid fibroblasts.
miR-181a suppresses PHLPP2 and negatively regulates the AKT pathway in human keloid fibroblasts
Further studies are required to explore the molecular mechanisms linking miR-181a with keloids. PHLPP2 was identified as a potential target of miR-181a from publicly available downregulation of PHLPP2 protein and mRNA expression by the miR-181a mimic, and conversely, upregulation by the miR-181a inhibitor, compared to the respective control groups. PHLPP2, a recently characterized member of the PHLPP family and suppressor of AKT signaling, is reported to inhibit cell cycle progression and promote cellular apoptosis [15] . Ectopic miR-181a expression in keloid fibroblasts increased the phosphorylated AKT protein level, whereas depletion of miR-181a decreased phosphorylated AKT protein expression to a significant extent (Fig. 4C and D) . We additionally measured PHLPP2 expression in both keloid and normal skin tissues. PHLPP2 expression was suppressed in keloid, compared with normal skin tissues (Fig. 4E) . These findings collectively indicate that the expression patterns of miR-181a and PHLPP2 are inversely correlated, supporting the theory that PHLPP2 is a direct downstream target of miR-181a. Given that miR-181a enhances cell proliferation, inhibits apoptosis and suppresses PHLPP2 in keloid fibroblast cells, we speculated that miR181a affects the phenotype of keloid fibroblasts via specific regulation of PHLPP2 3′UTR. To examine this hypothesis, we overexpressed PHLPP2 depleted of the 3′UTR region in keloid fibroblasts and measured the protein levels (Fig. 4F) . In addition, we observed its ability of cell proliferation and apoptosis. Notably, increased proliferation and decreased apoptosis were attenuated upon transfection of the PHLPP2 overexpression vector devoid of the 3′UTR region (Fig. 4G) . Accordingly, the expression of PCNA and cyclin D1 was attenuated, while cleaved caspase 9 expression was enhanced in PHLPP2+miR-181a mimic group compared with miR-181a group (Fig. 4H) . Based on the findings, we propose that proliferation and apoptosis of keloid fibroblasts are impaired via the miR-181a/ PHLPP2 signaling axis. 
miR-181a promotes proliferation of normal skin fibroblasts
We further examined whether overexpression of miR-181a affects the cell phenotype of normal fibroblasts. The EdU incorporation assay was performed to determine the effects of miR-181a on normal fibroblast proliferation. Notably, the number of EdU-positive normal fibroblasts in the miR-181a mimic transfection group was enhanced, relative to that of cells in the scramble control group (Fig. 5A) . We further confirmed the effects of miR-181a on cell proliferation using CCK-8 assay (Fig. 5B) . In addition, ectopic miR-181a expression in normal fibroblasts made a decrease in PHLPP2 expression and an increase in the phosphorylated AKT at protein levels (Fig. 5C ). All data signified that miR-181a acts as a stimulus for abnormal growth.
Discussion
In this study, we have demonstrated a role of miR-181a in human keloid fibroblast development via promotion of cell proliferation and inhibition of apoptosis. As expected, miR-181a inhibition markedly abrogated the proliferative ability of human keloid fibroblasts and induced apoptosis. At the molecular level, AKT pathways contribute to the miR-181a-mediated malignant phenotype of human keloid fibroblasts, possibly via inhibition of PHLPP2 expression. The above data clearly support a potential role of miR-181a in the development and progression of human keloid fibroblasts.
Recent evidence has suggested that miRNAs play important roles in fibrosis and they may be useful targets for treatment of the disease [16] . miR-181a is a multifaceted miRNA implicated in many cellular processes, including cell fate determination, proliferation and invasion. Earlier, Shi et al. [17] showed that miR-181a functions as a tumor suppressor by triggering growth inhibition, inducing apoptosis, and suppressing invasion in glioma cells. In contrast, miR-181a is reported to promote G1/S transition and cell proliferation in pediatric acute myeloid leukemia by targeting ATM [18] . Jianwei and colleges demonstrated that miR-181a improves proliferation and invasion and suppresses apoptosis of osteosarcoma cells [19] . Data from the current study showed that miR-181a is increased in human keloid fibroblasts, although its functions and molecular mechanisms remain to be established. Our findings provide comprehensive evidence of the functional, mechanical and clinical significance of this molecule. Firstly, we confirmed increased expression of miR-181a in human keloid tissues and fibroblasts, compared to normal skin tissues and fibroblasts, respectively. Next, we showed that miR-181a overexpression promotes cell proliferation and inhibits apoptosis, whereas miR-181a inhibition has the opposite effect. Further research is required to elucidate the molecular pathways mediating the different biological effects and targets of miR-181a in human keloid fibroblasts.
PHLPP2, a phosphatase essential for specific and effective termination of oncogenic AKT signaling, was identified as a target gene of miR-181a in the current study [20, 21] . PHLPP2, a tumor suppressor that inhibits cell growth and induces apoptosis in cancer cell lines [15] , is located at 16q22.3, a region that undergoes loss of heterozygosity (LOH) in breast and ovarian cancers, prostate cancer, and hepatocellular carcinoma [22] . However, the expression patterns and biological functions of PHLPP2 in human keloid fibroblasts remain to be established. PHLPP2 was determined as a target of miR-181a using bioinformatics analysis software, which was further verified using a double-luciferase reporter assay. Moreover, PHLPP2 was downregulated in human keloid tissues, compared with normal skin tissues. PHLPP2, a characterized member of the PHLPP family and suppressor of AKT signaling, inhibits cell cycle progression and induces apoptosis in various cancer cell types [21] . Accordingly, we examined the expression of phosphorylated and total AKT in keloid fibroblasts transfected with a miR-181a mimic, miR-181a inhibitor or the irrespective controls to clarify the pathway associated with PHLPP2 activity in keloid fibroblasts. The miR181a mimic suppressed PHLPP2 expression and enhanced phosphorylated AKT expression, suggesting that the miRNA inhibits apoptosis via blocking the phosphatidylinositol 3-kinase/ AKT pathway. The miR-181a inhibitor exerted the opposite effects. Moreover, the miR-181a mimic promoted normal skin fibroblast cell proliferation. Our collective data suggest that miR-181a negatively regulates PHLPP2 expression, and increases cell proliferation and inhibits apoptosis through activating the AKT pathway in keloid fibroblasts.
In summary, miR-181a promotes cell proliferation and inhibits apoptosis through suppressing PHLPP2 expression, leading to activation of the AKT pathway, and consequently, accelerated cell growth of keloid fibroblasts. Our findings support the potential utility of both miR-181a and PHLPP2 as novel biomarkers and targets for diagnostic and therapeutic approaches for keloids.
